L & S Advisors’s Filana Therapeutics FLNA Stock Holding History

L & S Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-6,000	Closed	-$513K	–	376
2021 Q2	$513K	Buy	+6,000	New	+$321K	0.06%	242

Other funds holding FLNA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

L & S Advisors's FLNA Position: Q3 2021 in Review

L & S Advisors sold out of Filana Therapeutics (FLNA) in Q3 2021, closing a stake of 6,000 shares — an estimated $513K sold.

L & S Advisors first reported a position in FLNA in Q2 2021 and held it in 1 quarter. The position peaked at $513K in Q2 2021. 180 funds tracked by Wall St. Rank hold FLNA as of Q3 2021.

L & S Advisors reported no remaining Filana Therapeutics position as of Q3 2021 after selling out during the quarter.
L & S Advisors sold 6,000 Filana Therapeutics shares in Q3 2021, an estimated $513K.
L & S Advisors first reported a position in Filana Therapeutics in Q2 2021 and held it in 1 quarter.
L & S Advisors's Filana Therapeutics position peaked at $513K in Q2 2021.
180 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2021.

Based on L & S Advisors's 13F filing for Q3 2021, filed 9 Nov 2021.